11C-Choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy

Journal of Nuclear Medicine

Volumn 55, Issue 2, 2014, Pages 233-241

  Giovacchini, Giampiero ^a   Picchio, Maria ^b   Garcia Parra, Rita ^c   Briganti, Alberto ^b   Abdollah, Firas ^b   Gianolli, Luigi ^b   Schindler, Christian ^d   Montorsi, Francesco ^b   Messa, Cristina ^c,e,f   Fazio, Ferruccio ^b,c  

^a Department of Radiology Stadtspital Triemli ^*  (Switzerland)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e CNR   (Italy)

^f SAN GERARDO HOSPITAL   (Italy)

Author keywords

Biochemical failure; PCa specific survival

Indexed keywords

CHOLINE C 11; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE; VERY ELDERLY; YOUNG ADULT; 11C-CHOLINE PET/CT; BIOCHEMICAL FAILURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; IMAGE PROCESSING; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODAL IMAGING; PATHOLOGY; PCA-SPECIFIC SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RADIOGRAPHY; SALVAGE THERAPY; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE;

11C-CHOLINE PET/CT; BIOCHEMICAL FAILURE; PCA-SPECIFIC SURVIVAL;

ANDROGEN ANTAGONISTS; CARBON RADIOISOTOPES; CHOLINE; DISEASE-FREE SURVIVAL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPH NODES; MALE; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84897933881     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.123380     Document Type: Article

References (38)

1. 18F]fluorodeoxyglucosepositron emission tomography. J Urol. 2003;169: 1337-1340.
2. 18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging. 2006;33: 1387-1398.
3. 11C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int. 2007;99: 1421-1426.
4. 11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35: 9-17.
5. 11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35: 18-23.
6. 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50: 1394-1400.
7. 11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184: 938-943.
8. 11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37: 301-309.
9. 11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37: 1106-1116.
10. 18F-fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging. Eur J Nucl Med Mol Imaging. 2011;38: 14-22.
11. 18F] fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39: 271-282.
12. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54: 833-840.
13. 11C-choline for PET in prostate cancer [Newsline]. J Nucl Med. 2012;53: 11N.
14. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12: 98-107.
15. 11Ccholine-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer. BJU Int. 2008;102: 446-451.
16. Giovacchini G, Gajate AM, Messa C, Fazio F. Increased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancer. Clin Nucl Med. 2008;33: 797-798.
17. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17: 948-957.
18. 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res. 2010;16: 6093-6099.
19. Freedland SJ, Humphreys EB, Mangold LA, et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007;25: 1765-1771.
20. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95: 1376-1383.
21. Zhou P, Chen MH, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23: 6992-6998.
22. Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25: 2035-2041.
23. American Joint Committee on Cancer. In: Edge SB, Byrd DR, Compton CC, April GF, Greene FL, Trotti A, eds. AJCC Cancer Staging Manual. New York, NY; 2010: 457-464.
24. Scher HI, Eisenberger M, D'Amico AV, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004;22: 537-556.
25. Scher HI, Morris MJ, Basch E, Heller G. End points and outcomes in castrationresistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol. 2011;29: 3695-3704.
26. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59: 572-583.
27. Fanti S, Krause B, Weber W, et al. Re: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;60: e37-38; author reply e39-41.
28. 11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60: 935-943.
29. 18F-fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol. 2013;63: 792-796.
30. 18F-choline PET/CT in patients with recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2012; 39: 936-943.
31. 11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy. Q J Nucl Med Mol Imaging. 2012;56: 440-446.
32. 18F] fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol. 2002;168: 273-280.
33. 11C- choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med. 2010;24: 485-492.
34. 18F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35: 253-263.
35. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61: 195-202.
36. 11C-choline PET/CT on the treatment planning for salvage radiation therapy in patients with biochemical recurrence of prostate cancer. Radiother Oncol. 2011;99: 193-200.
37. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing wholepelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21: 1904-1911.
38. Cheng L, Slezak J, Bergstralh EJ, et al. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer. 1999;86: 657-663.